GHRP-6

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6; development code SKF-110679) is a synthetic hexapeptide that acts as an agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). It was among the first growth-hormone-releasing peptides ever synthesized, emerging from work in the early 1980s by the American endocrinologist Cyril Y. Bowers and colleagues, who first described the sequence in Endocrinology in 1984. GHRP-6 is the chemical ancestor of the broader GHRP family, which later included GHRP-2, hexarelin, and the more selective ipamorelin.

GHRP-6 occupies an important place in the history of endocrinology. Because it released growth hormone (GH) through a receptor entirely distinct from growth-hormone-releasing hormone (GHRH), it helped reveal that a second, independent pathway for GH secretion existed. The hunt for the receptor that GHRP-6 activated culminated in the 1996 cloning of the growth-hormone-secretagogue receptor (GHS-R), and the search for that receptor's natural ligand led to the discovery of ghrelin in 1999.

Despite this scientific significance, GHRP-6 has never been approved as a therapeutic by the FDA, EMA, or any comparable regulator. Human research with it exists but is limited and largely mechanistic. A defining practical feature is that GHRP-6 strongly stimulates appetite and hunger through the ghrelin pathway, and it is non-selective: it also raises cortisol and prolactin.

Chemistry and structure

GHRP-6 is a short, fully synthetic peptide containing two D-configured amino acids, which help it resist enzymatic degradation relative to all-L peptides.

The sequence includes D-tryptophan (D-Trp) and D-phenylalanine (D-Phe), plus a C-terminal amide. In its original description, the peptide was designated [His¹,Lys⁶]GHRP. GHRP-6 is often supplied and stored as an acetate salt, which carries a different CAS registry number than the free peptide.

Mechanism of action

GHRP-6 binds and activates the GHS-R1a receptor, a G-protein-coupled receptor expressed in the anterior pituitary and the hypothalamus. This is the same receptor later shown to be the target of the endogenous hormone ghrelin. Receptor activation is coupled through the Gq/phospholipase-C pathway, increasing intracellular calcium and triggering release of stored GH from pituitary somatotrophs as a discrete pulse.

GHRP-6 does not bind the GHRH receptor. Its action is therefore mechanistically distinct from, and complementary to, GHRH analogs such as CJC-1295, which act on a separate receptor. The recognition of this separate pathway is what made GHRP-6 historically important: it demonstrated that GH could be released through a route independent of GHRH.

Beyond the pituitary, GHRP-6 engages central appetite circuitry. Like ghrelin, it activates orexigenic neuropeptide-Y (NPY)/agouti-related-peptide neurons in the hypothalamic arcuate nucleus and other appetite-related brain regions. In animal studies, the feeding effect of both ghrelin and GHRP-6 was blocked by an NPY-receptor antagonist, linking the appetite response to NPY signaling.

A second binding site, the scavenger receptor CD36, has been implicated in some tissue-protective (cytoprotective) effects of GHRP-6 in preclinical models, separate from GH release.

Research and evidence

It is important to separate GHRP-6's historical and mechanistic significance from the limited human clinical evidence. There are no large, long-term controlled human trials establishing GHRP-6 as a treatment for any condition.

Historical role in ghrelin-receptor discovery

• First synthesis (Bowers et al., 1984). The hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ was shown to release GH in a dose-related way in vitro and in vivo across several species (rat, monkey, lamb, calf) without concomitant release of LH, FSH, TSH, or prolactin in that early characterization.
• Receptor cloning (Howard et al., 1996). Researchers at Merck used GHRP-6 and the nonpeptide secretagogue MK-0677 to clone the growth-hormone-secretagogue receptor (GHS-R) from pituitary and hypothalamus, a landmark that characterized the receptor, an orphan GPCR at the time.
• Ghrelin (1999). The natural ligand of that receptor, ghrelin, was identified in 1999. GHRP-6 is thus a direct historical precursor to the entire ghrelin field.

Animal evidence

• Appetite/feeding (Lawrence et al., 2002). In rats, central GHRP-6 (like ghrelin) significantly stimulated food intake and activated multiple hypothalamic and brainstem appetite regions; the feeding effect was NPY-dependent.
• Cytoprotection (preclinical). Reviews summarize preclinical work exploring tissue-protective effects of GHRP-6 in cardiac, neuronal, hepatic, and gastrointestinal models, partly attributed to CD36 engagement. These remain animal-model findings.

Human evidence

• Neuroendocrine effects in humans (Frieboes et al., 1995). GHRP-6 raised nocturnal GH, but also increased ACTH and cortisol secretion and increased stage-2 sleep. The authors concluded GHRP-6 stimulates not only GH but also hypothalamic-pituitary-adrenocortical hormones, a key contrast with GHRH.

There are no large, long-term, controlled human trials supporting GHRP-6 for anti-aging, body composition, athletic performance, or other popularly marketed uses.

Safety and risks

Human safety data are limited to small, short studies, and GHRP-6 has not undergone the large-scale safety evaluation expected of an approved drug. Several effects are well documented and worth stating plainly:

• Strong appetite/hunger stimulation. Through the ghrelin pathway, GHRP-6 is a potent appetite stimulant. This is one of its most consistent and noticeable effects and distinguishes it from more selective secretagogues.
• Cortisol and ACTH elevation. Unlike GHRH (which tends to blunt cortisol) and unlike the more selective ipamorelin, GHRP-6 raises ACTH and cortisol, particularly at higher doses. Chronic elevation of cortisol is biologically undesirable.
• Prolactin elevation. GHRP-6 can raise prolactin, reflecting its non-selective neuroendocrine activity. (Note: the original 1984 animal characterization did not detect prolactin release, but human and later data describe prolactin among the off-target hormones affected by GHRPs.)
• GH/IGF-1 axis effects. As a GH secretagogue, class-level concerns associated with raising GH/IGF-1 signaling (for example effects on glucose handling, fluid retention, joint discomfort, or unmasking of occult conditions) are relevant considerations.
• Limited long-term data. Reviews of GH secretagogues note that safety data are constrained by short durations and small sample sizes; long-term safety (including any cancer or mortality signal) is not established.
• Product-quality risk. Material sold as "GHRP-6" in the research-chemical market is not subject to pharmaceutical quality control; purity, identity, and sterility cannot be assumed.

This section is descriptive, not a safety endorsement. No dosing guidance is provided.

Regulatory status

• It has no marketing approval from the FDA, EMA, or any comparable regulator for any indication.
• It is not a recognized prescription medication; it is distributed as a research chemical / laboratory reagent, commonly labeled "not for human consumption."
• Although GHRP-6 has been studied for decades and explored for various potential applications (including cytoprotection), it has not advanced to approval anywhere.

How it compares

The following is neutral and factual. None of these compounds is an approved general-use therapeutic, and all act on the GH axis or the ghrelin receptor.

The key contrasts: GHRP-6 and GHRP-2 are both first-generation, non-selective ghrelin-receptor hexapeptides that raise cortisol and prolactin, with GHRP-6 particularly associated with appetite stimulation. Ipamorelin was designed to be more selective, releasing GH while sparing the cortisol/prolactin axis. CJC-1295 works through the separate GHRH receptor, which is why GHRH analogs and GHS-R agonists are frequently discussed together — though combination claims circulating online go beyond what controlled human trials have established.

Legal status

• United States. Not FDA-approved for human use. Sold as a research chemical and commonly labeled "not for human consumption."
• Anti-doping (sport). GHRP-6 is prohibited at all times (in and out of competition) under the World Anti-Doping Agency (WADA) Prohibited List, within Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which explicitly covers growth hormone secretagogues and ghrelin-receptor agonists/mimetics. Athletes in WADA-governed sport must not use it.
• General. Regulatory and legal status varies by country; the absence of approval means there is no legitimate human-therapeutic channel for GHRP-6 in most jurisdictions.

Common misconceptions